Course Content
Blood & Immunology Module — 3rd Year MBBS
AIM • KMU EXAM PRACTICE

KMU Past Paper Practice

Hemostasis, Platelet Disorders, von Willebrand Disease, Hemophilia and DIC

3rd Year MBBS • 20 A-type Single Best Answer MCQs :contentReference[oaicite:0]{index=0}

MCQ 1

Question:

Following a small vascular injury, a patient has adequate circulating platelets but impaired attachment of platelets to exposed subendothelial collagen. Which interaction is most directly required for this initial step of primary hemostasis?

Options:

Factor VIII binding to factor IX
Fibrinogen binding to platelet GPIIb/IIIa
von Willebrand factor binding platelet GPIb to collagen
Thrombin converting fibrinogen into fibrin
Factor XIII cross-linking adjacent fibrin strands
Correct Answer:
von Willebrand factor binding platelet GPIb to collagen
Explanation: vWF bridges exposed subendothelial collagen to platelet GPIb, allowing the first platelet attachment after vascular injury.

MCQ 2

Question:

Platelets adhere normally at a site of injury and become activated, but they fail to form effective bridges with neighboring platelets. Which interaction is primarily responsible for normal platelet aggregation?

Options:

Fibrinogen binding to activated GPIIb/IIIa receptors
von Willebrand factor binding to factor VIII
Tissue factor binding to factor VII
Factor IX interacting with factor VIII
Plasmin binding to fibrin degradation products
Correct Answer:
Fibrinogen binding to activated GPIIb/IIIa receptors
Explanation: Activated GPIIb/IIIa binds fibrinogen, which bridges adjacent platelets and produces platelet aggregation.

MCQ 3

Question:

A patient generates thrombin and fibrin normally after vascular injury, but the resulting fibrin clot lacks adequate mechanical stability. Which coagulation factor normally performs the final stabilizing step?

Options:

Factor VII
Factor IX
Factor X
Factor XII
Factor XIII
Correct Answer:
Factor XIII
Explanation: Factor XIII cross-links fibrin strands after fibrin formation, producing a mechanically stable clot.

MCQ 4

Question:

A coagulation defect produces an abnormal test of the intrinsic pathway while the extrinsic pathway remains preserved. Which group contains factors belonging predominantly to the intrinsic pathway?

Options:

II, V, VII and X
VIII, IX, XI and XII
I, II, V and X
VII, X, V and II
V, VII, VIII and XIII
Correct Answer:
VIII, IX, XI and XII
Explanation: Factors XII, XI, IX and VIII constitute the traditional intrinsic pathway and are assessed mainly by aPTT.

MCQ 5

Question:

A patient develops thrombocytopenia after treatment that markedly suppresses bone-marrow activity. Unlike immune thrombocytopenia, the marrow is unable to mount an adequate platelet-producing response. Which mechanism best accounts for the low platelet count?

Options:

Increased platelet sequestration
Immune platelet clearance
Microvascular platelet consumption
Reduced platelet production
Accelerated fibrin breakdown
Correct Answer:
Reduced platelet production
Explanation: Bone-marrow suppression decreases megakaryocyte activity and therefore reduces platelet production rather than increasing peripheral destruction.

MCQ 6

Question:

A severely injured patient loses a large volume of blood and receives extensive replacement with fluids and blood components lacking adequate platelets. The platelet count subsequently falls despite previously normal marrow function. What is the most likely mechanism?

Options:

Autoimmune platelet destruction
Dilution of circulating platelets
Failure of factor VIII synthesis
Reduced von Willebrand factor activity
Selective splenic platelet destruction
Correct Answer:
Dilution of circulating platelets
Explanation: Major blood-volume replacement can dilute the patient’s circulating platelets, producing dilutional thrombocytopenia.

MCQ 7

Question:

A young woman with isolated thrombocytopenia is found to have IgG bound to circulating platelets. Which platelet structures are important antigenic targets in the pathogenesis of this disorder?

Options:

GPIIb/IIIa and GPIb-containing complexes
Factors VIII and IX complexes
Fibrin and fibrinogen complexes
Factors XI and XII complexes
Plasmin and plasminogen complexes
Correct Answer:
GPIIb/IIIa and GPIb-containing complexes
Explanation: ITP commonly involves IgG autoantibodies against platelet membrane glycoproteins, particularly GPIIb/IIIa and GPIb-containing complexes.

MCQ 8

Question:

A 30-year-old woman has symptomatic immune thrombocytopenia with bruising and mucosal bleeding but no immediately life-threatening hemorrhage. Which therapy most directly reduces the immune process responsible for platelet loss?

Options:

Factor IX replacement
Oprelvekin alone
Desmopressin therapy
Tranexamic acid alone
Corticosteroid therapy
Correct Answer:
Corticosteroid therapy
Explanation: Corticosteroids suppress immune-mediated platelet destruction and are a major treatment approach for symptomatic ITP.

MCQ 9

Question:

A patient with known immune thrombocytopenia develops a life-threatening intracranial hemorrhage with profound thrombocytopenia. In addition to treatment directed at the immune process, which supportive intervention is appropriate because of the immediate bleeding risk?

Options:

Factor VIII concentrate
Desmopressin administration
Platelet transfusion
Factor IX concentrate
Antifibrinolytic monotherapy
Correct Answer:
Platelet transfusion
Explanation: Platelet transfusion is generally reserved for major or life-threatening bleeding in ITP because transfused platelets may also undergo immune destruction.

MCQ 10

Question:

A woman with recurrent epistaxis and heavy menstrual bleeding has a normal platelet count and a normal prothrombin time. Further testing supports von Willebrand disease. Why can the prothrombin time remain normal in this condition?

Options:

Platelet production compensates for factor loss
Fibrinolysis is completely suppressed
Factor IX activity becomes increased
The extrinsic coagulation pathway remains intact
Thrombin generation becomes accelerated
Correct Answer:
The extrinsic coagulation pathway remains intact
Explanation: PT assesses the extrinsic and common pathways, which are not primarily defective in von Willebrand disease.

MCQ 11

Question:

A boy has recurrent deep bleeding. His maternal uncle had a similar disorder, while his father is unaffected. Factor assay confirms hemophilia. Which inheritance pattern best explains this family history?

Options:

X-linked recessive inheritance
Autosomal dominant inheritance
Autosomal recessive inheritance
Mitochondrial inheritance
Y-linked inheritance
Correct Answer:
X-linked recessive inheritance
Explanation: Hemophilia A and B classically follow X-linked recessive inheritance, producing disease mainly in males through carrier females.

MCQ 12

Question:

A 17-year-old boy with severe hemophilia has experienced repeated episodes of bleeding into both knees since childhood. He now has chronic pain and limitation of movement. Which process most directly explains the current joint problem?

Options:

Immune destruction of articular platelets
Microvascular fibrin deposition in cartilage
Progressive damage from recurrent hemarthroses
Defective platelet adhesion to synovium
Excessive fibrinolysis within bone marrow
Correct Answer:
Progressive damage from recurrent hemarthroses
Explanation: Repeated bleeding into joints causes chronic structural damage and can lead to hemophilic arthropathy.

MCQ 13

Question:

A boy with hemophilia initially appears to stop bleeding after a minor procedure, but bleeding restarts several hours later. Platelet number and function are preserved. Which defect best explains the delayed bleeding?

Options:

Failure of platelet adhesion to collagen
Reduced platelet release of ADP
Excessive splenic platelet sequestration
Failure of platelet fibrinogen receptors
Inadequate fibrin reinforcement of the platelet plug
Correct Answer:
Inadequate fibrin reinforcement of the platelet plug
Explanation: Primary hemostasis can occur in hemophilia, but defective secondary hemostasis prevents adequate fibrin stabilization of the initial plug.

MCQ 14

Question:

A patient with established hemophilia A develops significant bleeding after trauma. The clinician wants to correct the deficient coagulation protein directly. Which treatment best addresses the underlying defect?

Options:

Platelet transfusion
Factor VIII replacement
Factor IX replacement
Oprelvekin therapy
Intravenous immunoglobulin
Correct Answer:
Factor VIII replacement
Explanation: Hemophilia A results from factor VIII deficiency, so factor VIII replacement directly restores the missing coagulation activity.

MCQ 15

Question:

A patient with a coagulation-factor deficiency requires an adjunct that reduces fibrin clot breakdown. Tranexamic acid is unavailable. Which alternative drug works through the same general antifibrinolytic principle?

Options:

Desmopressin
Oprelvekin
Factor IX concentrate
Aminocaproic acid
Intravenous immunoglobulin
Correct Answer:
Aminocaproic acid
Explanation: Aminocaproic acid, like tranexamic acid, inhibits fibrinolysis and helps preserve an already formed fibrin clot.

MCQ 16

Question:

A patient begins antifibrinolytic therapy for recurrent bleeding and subsequently reports nausea and abdominal discomfort without evidence of thrombosis. Which adverse effect category best fits these symptoms?

Options:

Gastrointestinal adverse effects
Immune platelet destruction
Coagulation-factor depletion
Megakaryocyte suppression
von Willebrand factor depletion
Correct Answer:
Gastrointestinal adverse effects
Explanation: Antifibrinolytic drugs can cause gastrointestinal symptoms such as nausea and abdominal discomfort in addition to concern about thrombosis.

MCQ 17

Question:

A hematopoietic supportive drug is prescribed to increase platelet production by promoting megakaryocyte development and maturation. The pharmacological agent is a recombinant form of which mediator?

Options:

Interleukin-2
Interleukin-6
Interleukin-8
Interleukin-11
Interleukin-12
Correct Answer:
Interleukin-11
Explanation: Oprelvekin is recombinant interleukin-11 and promotes megakaryocyte maturation, thereby increasing platelet production.

MCQ 18

Question:

A patient with a newly diagnosed hematological malignancy develops a rapidly evolving consumption coagulopathy with diffuse bleeding. Which malignancy is a particularly important association with this complication?

Options:

Chronic lymphocytic leukemia
Acute promyelocytic leukemia
Multiple myeloma
Hodgkin lymphoma
Chronic myeloid leukemia
Correct Answer:
Acute promyelocytic leukemia
Explanation: Acute promyelocytic leukemia is an important malignancy associated with DIC and may produce severe consumption of hemostatic factors.

MCQ 19

Question:

A patient suffers extensive crush injuries in a road traffic accident. Several hours later, laboratory findings indicate systemic activation of coagulation with consumption of platelets and clotting factors. Which aspect of the original injury most strongly predisposed to this process?

Options:

Transient reduction in platelet adhesion
Inherited factor IX deficiency
Reduced von Willebrand factor release
Isolated splenic sequestration
Extensive tissue injury
Correct Answer:
Extensive tissue injury
Explanation: Major trauma and extensive tissue injury can strongly activate systemic coagulation and precipitate DIC.

MCQ 20

Question:

A patient with systemic coagulation activation develops widespread fibrin deposition. At the same time, the body attempts to remove the deposited fibrin, contributing further to the complex bleeding pattern. Which process is responsible for this response?

Options:

Enhanced megakaryocyte maturation
Increased platelet sequestration
Secondary activation of fibrinolysis
Reduced factor VIII degradation
Enhanced von Willebrand factor synthesis
Correct Answer:
Secondary activation of fibrinolysis
Explanation: Widespread fibrin formation in DIC activates secondary fibrinolysis, producing fibrin breakdown products and contributing to the bleeding tendency.
Scroll to Top
💬 WhatsApp Support